title: Insights from next generation sequencing of the cancer genome.
abstract: This detailed review provides a history and update of the complex field of cancer genetics. Using examples of progress such as the development of imatinib for chronic myeloid leukemia (which stemmed from the recognition of the Philadelphia chromosome in the 1960s), Michael Stratton, Director of the Sanger Institute in Cambridge is confident that we are now entering the end game of cancer genome sequencing. This has led to other drug therapies, based on knowledge of the molecular changes in some cancers, lung and breast cancers for example.
authors.affiliation: NHS Lothian, Edinburgh, UK. mary.porteous@ed.ac.uk
authors.forename: M
authors.initials: M
authors.lastname: Porteous
mesh_terms: D001483:Base Sequence; D015894:Genome, Human; D023281:Genomics / Q000266:history; D006666:History of Medicine; D049673:History, 20th Century; D006801:Humans; D009369:Neoplasms / Q000235:genetics* / Q000266:history; D017422:Sequence Analysis, DNA / Q000266:history